Results of the National Equine Veterinary Economic Study provide an in-depth assessment of the equine veterinary industry, including the current status and economic trends of veterinary practices, and attitudes of veterinarians. Study results will be released in a series of six monthly topics, and the first release provides a financial review of the equine veterinary industry from 2007 to 2012.
Data from the study reflect, among other things, a significant downturn in key economic indicators for equine practices from 2008 to 2010, including revenues, invoices, and number of active patients and clients. This was followed by a rebound in 2011 and 2012, but not a complete recovery.
Sponsored by Merck Animal Health (known as MSD Animal Health outside the United States and Canada) and Henry Schein Animal Health, in partnership with the American Association of Equine Practitioners (AAEP), the study was led by equine veterinary market research specialist and practice management consultant, Edward L. Blach, DVM, MS, MBA, and assisted by Andrew R. Clark, DVM, MBA, a leading equine practice management consultant.
The study also includes an evaluation of current management practices to help identify ways equine practices can operate in a more profitable manner.
“For example, more work is being concentrated on fewer clients and fewer horses, which is a significant change to the business landscape–impacting business practices, revenue streams and client management,” said Blach.
“Until now, little equine veterinary economic data has been available to help veterinarians develop improved strategies to grow their practices,” said Brett Whitehead, Merck Animal Health director of equine business. “This study puts better, more practical information in the hands of equine veterinarians, which, in turn, gives them greater confidence to invest in efforts that will support growth of their business.”
“The equine industry has weathered a tough economic environment since 2007, and it has certainly taken its toll on equine veterinary practices,” said Jeannie Jeffery, Henry Schein Animal Health national director of equine sales. “In spite of these challenges, equine veterinarians are cautious but seem to be committed to the profession.”
Equine veterinarians interested in learning more and receiving updates on the study results, as well as access to valuable economic and practice management tools and information, should visit IsMyPracticeHealthy.com to register and be added to the mailing list.
Study methodology: Data were collected from nearly 500 AAEP-member veterinarian survey respondents, including practice owners, veterinary associates, academic veterinarians, industry veterinarians, students and retired veterinarians.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
